| Chair: Ander Urruticoechea, Onkologikoa, San Sebastián, Spain |
|
| 16:00 - 16:20 | ESMO guidelines for breast cancer: how are they made? Curigliano Giuseppe, European Institute of Oncology, Milan, Italy |
| 16:20 - 16:40 | Adherence to oral breast cancer therapies Iván Bustillos, Clínica Portoazul Auna, Barranquilla, Colombia |
| 16:40 - 17:00 | De-escalation of antineoplastic therapies: Principles and considerations Henk Van Halteren, Adrz-Admiraal de Ruijter Medical Center, Goes, Netherlands |
| 17:00 - 17:30 | Discussion |
| Chair: José Enrique Alés, Centro de Patología de la Mama - Fundación Tejerina, Madrid, Spain |
|
| 17:45 - 18:05 | What have we seen from oral SERDs and what could they mean for our patients in future? Aditya Bardia, Massachusetts General Hospital Cancer Center, Boston, USA |
| 18:05 - 18:25 | Safety management of Antibody-Drug-Conjugates Maryam Lustberg, Yale University School of Medicine, New Haven, USA |
| 18:25 - 18:45 | Managing brain metastases for HER2+ breast cancer Diana Lüftner, Charité Campus Benjamin Franklin, Medizinische Klinik III, Berlin, Germany |
| 18:45 - 19:15 | Discussion |
| Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain |